Status: Recruiting
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.
Participants needed: 74
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Xinhua Zhang, MDUpdated: Feb 26, 2025Locations: 1
Eligibility criteria
Patients who are aged ≥ 18 years. [+6]
KIT or PDGFRA wild type. [+2]